WhaleWatch

DATE17 Aug

NIFTY 24,288 ▼ 0.32%BANK NIFTY 57,498 ▲ 0.01%NIFTY IT 30,808 ▼ 1.75%NIFTY PHARMA 26,342 ▼ 0.39%SCHNEIDER 1,212 ▼ 11.47%IPCALAB 1,885 ▲ 8.67%HINDCOPPER 573 ▲ 8.24%PTCIL 20,584 ▲ 8.05%BELRISE 236 ▼ 7.54%GPIL 251 ▲ 6.54%NSLNISP 42 ▼ 6.16%INOXWIND 78 ▲ 6.05%FINCABLES 1,321 ▲ 5.93%MOTILALOFS 955 ▲ 5.68%NIFTY 24,288 ▼ 0.32%BANK NIFTY 57,498 ▲ 0.01%NIFTY IT 30,808 ▼ 1.75%NIFTY PHARMA 26,342 ▼ 0.39%SCHNEIDER 1,212 ▼ 11.47%IPCALAB 1,885 ▲ 8.67%HINDCOPPER 573 ▲ 8.24%PTCIL 20,584 ▲ 8.05%BELRISE 236 ▼ 7.54%GPIL 251 ▲ 6.54%NSLNISP 42 ▼ 6.16%INOXWIND 78 ▲ 6.05%FINCABLES 1,321 ▲ 5.93%MOTILALOFS 955 ▲ 5.68%

Morning brief · Thursday, 20 August 2026

Aimtron's 162% surge may just be the start

Market pulse

Indian markets ended the recent session with a slight retreat as the benchmark Nifty dipped to 24,288, weighed down by a notable 1.75 percent slide in the IT index, while the Bank Nifty index managed to close nearly unchanged. Individual stocks saw sharp moves, with Ipca Labs and Hind Copper both rallying over eight percent, in contrast to Schneider Electric which plunged more than eleven percent.

From the investor's mind

One post worth your time, explained

@unseenvalue · on X

Sajal Kapoor observes that Sona Comstar experienced significant fluctuations, with its "Bhaw Bhagwaan" at ₹750 in 2021, dropping to ₹450 in 2025, and then rising above ₹800 in 2026. This volatility, described as "time correction + Bhaw correction," can eliminate market "fancy," a phenomenon Kapoor also noted with Laurus Labs between 2021 and 2023. Kapoor's key takeaway is that these corrections can present an opportunity to acquire shares of a fundamentally sound business at a more reasonable valuation.

Know more about the stock

Word in the street

What the wider market is buzzing about

Aimtron

₹1,743Past year ▲ 162%M.cap ₹2,338 Cr

One name on everyone’s lips this week was Aimtron, a company whose stock has soared 162.1 percent in the past year. After a sharp rerating, some investors believe the market has finally woken up to its potential, a view supported by a strong Q1 update and recent research coverage from Nuvama. Others feel the market still has not priced in the full story. They point to a future where FY27 revenue could reach ₹550-600 crore, partly through contributions from ICS. This growth could potentially bring its forward price to earnings ratio down significantly. With around 420 prototypes in development, the conversation now turns to how effectively Aimtron can commercialize its pipeline.

Know more about the stock

Yesterday's big moves